Boulding Mark Elliott

Exec. VP And CLO | Exec. VP And CLO

1 company

Good

Trades Analyzed

12M Win Rate

30.0%

Avg 3M Return

+0.4%

Avg 12M Return

-12.5%

Boulding Mark Elliott is an Exec. VP And CLO at PTC THERAPEUTICS, INC.. Recent SEC Form 4 filings include 0 buys and 24 sells.

Estimated insider holdings value: $8.5M based on current market prices.

Holdings by Company

PTCTApr 6, 2026

Current Shares107.5K

Value$8.49M

Net Activity-635,367

Bought: 0Sold: 635.4K

Showing 10 filings (page 3)

Date	Ticker	Role	Type	Shares	Price	Value	Chg%	3M	12M
Jan 9, 2023	PTCT Ptc Therapeutics, Inc.	Exec. VP And CLO	Sell	835	$41.66	$34,782.93	-1.1%	+16.9%	-31.0%
Oct 18, 2022	PTCT Ptc Therapeutics, Inc.	Exec. VP And CLO	Sale+OE	6,901	$55.00	$379,571.93	-2.7%	-2.1%	-58.0%
Sep 20, 2022	PTCT Ptc Therapeutics, Inc.	Exec. VP And CLO	Sale+OE	1,176	$55.00	$64,680.00	-1.0%	-27.6%	-51.6%
Apr 13, 2022	PTCT Ptc Therapeutics, Inc.	Exec. VP And CLO	Sale+OE	2,276	$45.17	$102,811.47	-3.6%	-3.4%	+9.3%
Apr 5, 2022	PTCT Ptc Therapeutics, Inc.	Exec. VP And CLO	Sale+OE	5	$45.00	$225.00	-	+0.3%	+8.7%
Feb 10, 2022	PTCT Ptc Therapeutics, Inc.	Exec. VP And CLO	Sale+OE	17,935	$45.03	$807,559.25	-12.8%	-29.4%	+3.6%
Feb 1, 2022	PTCT Ptc Therapeutics, Inc.	Exec. VP And CLO	Sell	779	$40.00	$31,161.56	-1.3%	-10.7%	+16.9%
Jan 7, 2022	PTCT Ptc Therapeutics, Inc.	Exec. VP And CLO	Sell	885	$38.53	$34,094.63	-1.8%	+12.9%	+3.2%
Sep 2, 2021	PTCT Ptc Therapeutics, Inc.	Exec. VP And CLO	Sale+OE	3,363	$45.01	$151,375.36	-6.5%	-19.4%	+16.3%
Jul 9, 2021	PTCT Ptc Therapeutics, Inc.	Exec. VP And CLO	Sale+OE	9,234	$45.19	$417,273.76	-1.9%	-17.2%	+0.6%